NASDAQ$CTMX
CytomX Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings ·
Briefing
CytomX Therapeutics reported Q1 2025 revenue of $50.9M, net income of $23.5M, diluted EPS of $0.27.
For Q1 2025, CytomX Therapeutics reported Revenue was $50.9M, net income was $23.5M, diluted EPS was $0.27. Management discusses operating trends, liquidity, and outlook in the quarterly filing.
- Revenue $50.9M for Q1 2025.
- Net income $23.5M.
- Diluted EPS $0.27.
Headline financials
Revenue & EPS history
CytomX Therapeutics Inc · Revenue · Quarterly
$50.9M
Forward guidance
The quarterly filing discusses operating priorities, capital allocation, and sector risks.
Tailwinds
- MD&A outlines strategic priorities and liquidity.
- Segment commentary supports the earnings narrative.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items can affect year-over-year comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+3.6%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+2.5%
Avg return
30 days after
53%
16 / 30 earnings
Positive
+129.5%
Q1 2025
Best reaction
-19.3%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.4% | -6.3% | -27.8% | |
| Q4 2025 | -19.3% | -34.1% | -27.6% | |
| Q3 2025 | -0.5% | -2.6% | -6.2% | |
| Q1 2025 | +129.5% | +118.8% | +203.9% | |
| Q3 2024 | +0.0% | +4.0% | +18.0% | |
| Q2 2024 | +1.7% | +0.0% | +3.4% | |
| Q1 2024 | +2.9% | -53.6% | -59.7% | |
| Q3 2023 | +0.8% | -7.9% | +15.0% | |
| Q2 2023 | -0.6% | -1.2% | -18.8% | |
| Q1 2023 | +2.4% | +6.0% | +3.6% | |
| Q3 2022 | -1.6% | +3.2% | +29.6% | |
| Q2 2022 | +3.8% | +1.9% | -7.0% | |
| Q1 2022 | -5.8% | +4.1% | +4.1% | |
| Q3 2021 | -2.0% | +14.8% | +8.4% | |
| Q2 2021 | +3.8% | -12.0% | -7.9% | |
| Q1 2021 | -4.5% | -4.5% | -20.6% | |
| Q3 2020 | +0.0% | +5.7% | +4.7% | |
| Q2 2020 | +1.3% | -6.2% | -11.9% | |
| Q1 2020 | +1.7% | +21.5% | -33.1% | |
| Q3 2019 | +0.8% | -9.8% | +3.1% | |
| Q2 2019 | +2.6% | -7.3% | -19.9% | |
| Q1 2019 | -0.1% | +7.2% | +3.4% | |
| Q3 2018 | -8.8% | +7.3% | -1.1% | |
| Q2 2018 | +1.6% | -4.2% | -19.4% | |
| Q1 2018 | +0.9% | -3.6% | +2.2% | |
| Q3 2017 | -1.7% | -1.4% | +0.4% | |
| Q2 2017 | +0.2% | +2.6% | +23.1% | |
| Q1 2017 | +2.3% | -0.2% | -2.3% | |
| Q3 2016 | -2.8% | -5.7% | -2.3% | |
| Q2 2016 | +3.2% | +10.8% | +19.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro